

Schedule

Wednesday, Nov. 1, 2023 8 a.m.–12:45 p.m. PDT

Registration

Time: **6:30 a.m.–6 p.m. PDT**
 Location: **Ground Level - Lobby D - San Diego Convention Center**

Breakfast

Time: **7–8 a.m. PDT**
 Location: **Upper Level - Ballroom 6AB**

Introduction

8–8:05 a.m. **Organizer Introduction**
 Bernard Fox, PhD – *Earle A. Chiles Research Institute*
 Tanja de Gruijl, PhD – *Amsterdam University Medical Centers*
 Joe Yeong, MD, PhD – *Singapore General Hospital*

Session 1: Clinical Studies

Time: **8:05–9:25 a.m. PDT**

8:05–8:15 a.m. **Combined immunotherapy improves outcome for replication repair deficient (RRD) high-grade glioma failing anti-PD1 monotherapy: a report from the international RRD Consortium**
 Anirban Das, MD – *Canadian Cancer Immunotherapy Consortium (CCIC)*

8:15–8:25 a.m. **RANK/RANKL, ERBB-2 and immunotherapy as a putative treatment strategy in ERBB-2 positive breast carcinomas**
 Evangelos Koustas, MD, PhD – *University of Athens (National Greek Organization)*

8:25–8:35 a.m. **Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer: from bench to a phase II clinical trial**
 Lesley Wu, MD – *Chinese American Hematology Oncology Network (CAHON)*

8:35–8:45 a.m. **Total neoadjuvant chemotherapy in locally advanced gastric and gastroesophageal junction cancer (OCTASUR)**
 Mykyta Pepenin, MD – *Ukraine (Peace & Development Foundation)*

Schedule

8:45–8:55 a.m.

Deciphering the molecular and immunological interaction in patients with hepatocellular carcinoma of viral and non-viral etiologies

Vincent Chien-Huai Chuang, MD – *The Taiwanese Oncology Society (TOS)*

8:55–9:15 a.m.

Panel/Q&A

9:15–9:25 a.m.

Break

Session 2: NK/T-Cells

Time:

9:25–10:20 a.m. PDT

9:25–9:35 a.m.

Tumor-redirected iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells

Gloria Delfanti, PhD – *Italian Network for Tumor Biotherapy (NIBIT)*

9:35–9:45 a.m.

Targeting HLA-E positive cancers with a novel NKG2A/C switch receptor

Lamberto Torralba Raga, PhD – *Scandinavian Network for Immunotherapy of Cancer (SNIC)*

9:45–9:55 a.m.

High salt diet promotes NK cells and gut microbiota-dependent anti-tumor immunity

Zaigham Abbas Rizvi, PhD – *Immuno-Oncology Society of India (I-OSI)*

9:55–10:10 a.m.

Panel/Q&A

10:10–10:20 a.m.

Break

Session 3: T-Cells and the Tumor Microenvironment

Time:

10:20–11:25 a.m. PDT

10:20–10:30 a.m.

CD8-IL2v potentiates intratumoral CD8 T cells to functionally respond to antigen recognition

Paulien Kaptein, PhD candidate – *KWF Dutch Tumor Immunology Meeting (KWF-DTIM)*

10:30–10:40 a.m.

Metabolic manipulation reveals heterogeneity in development of TCF1+ progenitor populations

Geoffrey Markowitz, PhD – *Society for Immunotherapy of Cancer (SITC)*

10:40–10:50 a.m.

Intratumoral regulatory T cell clones originate from regulatory T cells in tumor-draining lymph nodes

Hiroyasu Aoki, MD/PhD candidate – *Japanese Association of Cancer Immunology (JACI)*

Schedule

Schedule

10:50–11 a.m.	An integrated prognostic and immunotherapeutic predictive model based on comprehensive single cell-originated signature of tumor microenvironment in lung adenocarcinoma Jiachen Xu, MD – <i>Chinese Society for Clinical Oncology (CSCO)</i>
11–11:15 a.m.	Panel/Q&A
11:15–11:25 a.m.	Break
Session 4: New Avenues	
Time:	11:25 a.m.–12:20 p.m. PDT
11:25–11:35 a.m.	Chimeric DNA vaccination against the chondroitin sulfate proteoglycan 4 as an effective strategy to induce targeted immunity for the treatment of melanoma and osteosarcoma Federica Riccardo, PhD – <i>Progress in Vaccination Against Cancer (PIVAC)</i>
11:35–11:45 a.m.	CD84 a novel target for CAR T-cell therapy for acute leukemia Lorena Pérez-Amill, PhD – <i>Spanish Group of Immuno-Biological Therapeutics in Cancer (GETICA)</i>
11:45–11:55 a.m.	Adverse events of anti-PD-1 treatment and the impact of sex—what we know and what we are looking for Margaret Ottaviano, MD, PhD – <i>Società Campana di ImmunoTerapia Oncologica (SCITO)</i>
11:55 a.m.–12:05 p.m.	The versatility of proteomics: enabling immunomonitoring and personalized medicine in immunotherapy Parthiban Periasamy, PhD – <i>Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC)</i>
12:05–12:20 p.m.	Panel/Q&A
Closing Statement	
12:20–12:35 p.m.	Awards
12:35–12:45 p.m.	Conclusion
WIC Reception	
Time:	5:45–6:45 p.m. PDT
Location:	Upper Level - West Terrace - San Diego Convention Center